ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0287

6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease

(0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0589

A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE

(0582–0608) SLE – Treatment Poster I

9:00AM-11:00AM: Abstract Number: 0487

A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis

(0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

9:00AM-11:00AM: Abstract Number: 0228

A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0171

A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0665

A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0632

A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0274

A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0430

A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis

(0423–0459) RA – Treatments Poster I

9:00AM-11:00AM: Abstract Number: 0655

A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0264

A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0033

A Novel Transcriptome-Based Machine Learning Pipeline Predicts Phenotypes of Lupus Patients

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0030

A Pathogenetic Model of IgG4-related Disease Developed from Familial IKZF1 and UBR4 Gene Variants

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0571

A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0700

A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

1
2
3
…
59
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].